Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BeBetter MedSHSE:688759 -4.18%4 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates SHSE:688759 with a GF Score™ of 4/100. Among 701 Biotechnology companies, BeBetter Med ranks worse than 142653.21% on this metric.
The historical rank and industry rank for BeBetter Med's Days Payable or its related term are showing as below:
During the past 7 years, BeBetter Med's highest Days Payable was 13773.57. The lowest was 7253.16. And the median was 8609.31.
SHSE:688759's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.36 * Ranked among companies with meaningful Days Payable only.
BeBetter Med's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
BeBetter Med Days Payable Related Terms
BeBetter Med Days Payable Historical Data
* Premium members only.
The historical data trend for BeBetter Med's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688759 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, BeBetter Med's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeBetter Med Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeBetter Med's Days Payable distribution charts can be found below:
* The bar in red indicates where BeBetter Med's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
BeBetter Med's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeBetter Med (SHSE:688759) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BeBetter Med and its competitors. Over the past decade, BeBetter Med's Days Payable has ranged from 7,253.16 to 13,773.57. According to the industry distribution chart, BeBetter Med ranks #999999 out of 701 companies in the Biotechnology industry.
Is BeBetter Med's Days Payable too high?
BeBetter Med's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 7,253.16 to a high of 13,773.57. Based on the distribution chart, BeBetter Med ranks #999999 out of 701 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BeBetter Med has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BeBetter Med's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BeBetter Med ranks #999999 out of 701 companies for Days Payable. This places BeBetter Med in the lower half of its industry. The industry median Days Payable is 113.36. Historically, BeBetter Med's own Days Payable has ranged from 7,253.16 to 13,773.57 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.36, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on BeBetter Med and its competitors. For the Biotechnology industry, the median Days Payable is 113.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BeBetter Med's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeBetter Med stock overvalued right now?
BeBetter Med (SHSE:688759) has a current Days Payable of 0.00. The current Days Payable is 0.00. BeBetter Med's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For BeBetter Med (SHSE:688759), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BeBetter Med Inc is a biopharmaceutical company based in China, focusing on independent research and development of drugs. The company focuses on developing novel medicines for treating cancers, autoimmune diseases, and other severe conditions. Key products include the PI3K/HDAC dual inhibitor BEBT-908 and multiple drugs in clinical trial phases targeting cancers. It's a United States subsidiary BeBetter Pharma specializes in next-generation siRNA therapeutics using proprietary delivery platforms aimed at complex diseases like kidney disorders, metabolic and liver diseases, and neurodegenerative conditions. Its pipeline includes oral and injectable drug candidates, some in late-stage trials, and aims to address unmet medical needs through novel mechanisms.
4GF Score
Get the complete analysis for SHSE:688759
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688759 has been successfully added to your 
